Photodynamic therapy and immunity

IDrugs

Volumn 2, Issue 3, 1999, Pages 231-236

  Hunt, David W C ^a   Chan, Agnes H ^a  

^a QLT PhotoTherapeutics Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; FAS ANTIGEN; FAS LIGAND; HEMATOPORPHYRIN DERIVATIVE; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; PHOTOFRIN; PHOTOSENSITIZING AGENT; SINGLET OXYGEN; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; CELLULAR IMMUNITY; DISEASE SEVERITY; HUMAN; IMMUNE MEDIATED INJURY; IMMUNOMODULATION; IMMUNOSTIMULATION; NONHUMAN; PHOTODYNAMIC THERAPY; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

EID: 0032966228     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Doughery TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J, Peng Q: Photodynamic therapy. J Natl Cancer Inst (1998)90:889-905.
2. Levy JG: Photosensitizers In photodynamic therapy. Sem Onco/(1994) 21:4-10.
3. Levy JG: Photodynamic therapy. Trends Bhtech (1995) 13:1417.
4. Pass HI: Photodynamic therapy in oncology: Mechanisms and clinical use. JNati Cancer Inst (1993) 85:443-456.
5. Henderson BW, Dougherty TJ: How does photodynamic therapy work? Photochem Photobiol (1992) 55:145-157.
6. Kennedy JC, Pettier RH, Pross DC: Photodynamic therapy with endogeous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol (1990) 6:143-148.
7. Richter AM, Kelly B, Chow J, Uu DJ, Towers GHN, Dolphin D, Levy JG: Preliminary studies on a more effective phototoxic agent than hematoporphyrin. J Nati Cancer Inst (1987) 79:13271332.
8. Stemberg E, Dolphin D: Pyrrolic photosensitizers. Curr Med Chem (1996) 3:239-272.
9. Gomer CJ, Ferrario A, Hayashi N, Rucker N, Szirth BC, Murphree AL Molecular, cellular and tissue responses following photodynamic therapy. Lasers Surg Med (1988) 8:450-463.
10. Gomer, CJ, Rucker N, Ferrario A, Wong S: Properties and applications of photodynamic therapy. Radiât Res (1989) 120:1-18.
11. Agrarwal ML, day ME, Harvey EJ, Evans HH, Antunez AR, Oieinick ML Photodynamic therapy induces rapid cell death by apoptosis in L5178Y mouse lymphoma cells. Cancer Res (1991)51:5993-5996.
12. Granville DJ, Carthy CM, Hunt DW, McManus BM: Apoptosis: molecular aspects of cell death and disease. Lab Invest (1998) 78:893-913.
13. Granville DJ, Levy JG, Hunt DWC: Photodynamic therapy induces the caspase-3 activation in HL-60 cells. Cell Death arid Different (1997) 4:623-628.
14. Granville DJ, Carthy CM, Jiang H, Shore GC, McManus BM, Hunt DWC: Rapid cytochrome c release, activation of caspases 3, 6, 7 and 8 followed by Bap31 cleavage in HeLa cells treated with photodynamic therapy. FEBS Lett (1998) 437:5-10.
15. Kroemer G, Zamzami N, Susin SA: Mitochondria! control of apoptosis. Immunol Today (1997) 18:44-51.
16. Jiang H, Granville DJ, McManus BM, Levy JG, Hunt DWC: Selective depletion of a thymocyte sub-population in vitro with an immunomodulatory porphyrin photosensrtizer. Clin Immunol In press.
17. Reiter I, Schwamberger G, Krammer B: Effect of photodynamic pretreatment on the susceptibility of murine tumor cells to macrophage antitumor mechanisms. Photochem Photobiol ,(1997)66:384-388.
18. Shumaker BP, Hetze! FW: Clinical laser photodynamic therapy in the treatment of bladder cancer. Photochem Photobiol (1987) 46:899-901.
19. Nseyo UO, Whalen RK, Duncan MR, Berman B, Lundal SL Urinary cytokines following photodynamic therapy for bladder cancer. A preliminary report Urology (1990) 36:167171
20. Korbelik M, Krosl G: Enhanced macrophage cytotoxicity against tumor cells treated with photodynamic therapy. Photochem Photobiol (1994) 60:497-502.
21. Yamamoto N, Sery TW, Hoober JK, Willett NP, Undsay DD: Effectiveness of Photofrin II In activation of macrophages and In vitro killing of retinoblastoma cells. Photochem Photobiol (1994) 60:160-164.
22. Henderson BW, Donovan JM: Release of prostaglandin E, from cells by photodynamic treatment in vitro. Cancer Res (1989)49:6896-6900.
23. Evans S, Matthews W, Perry R, Fraker D, Norton J, Pass HI: Effect of photodynamic therapy on tumor necrosis factor production by murine macrophages. J Nat! Cancer Inst (1990) 82:34-39.
24. Kick G, Messer, Goetz, Plewig, Kind P: Photodynamic therapy Induces expression of interleukin 6 by activation of AP-1 but not NF-KB DNA binding. Cancer Res (1995) 55:2373-2379. -
25. Gollnick SO, u'u X, Owczarczak B, Mussér DA)-Henderson BW: Altered expression of interleukin 6 and interleukin 10 as a result of photodynamic therapy in vivo. Cancer Res (1997)57:3904-3909.
26. Korbelik M: Induction of tumor immunity by photodynamic therapy. J din Laser MedSurg (1996) 14:329-334.
27. Krosl G, Korbelik M, Dougherty GJ: Induction of immune cell infiltration Into murine SCCVII tumor by photofrin-based photodynamic therapy. BrJ Cancer (1995) 71:549-555.
28. Korbelik M, Cede I: Enhancement of tumor response to photodynamic therapy by adjuvant mycobacterium cell-wall treatment J Photochem Photobiol B (1998) 44:151-158.
29. Hryhorenko E, Rittenhouse-Diakun K, Harvey NS, Morgan J, Stewart CC, Oseroff AR: Characterization of endogenous protoporphyrin IX Induced by S-amino-levulinic acid in resting and activated peripheral blood lymphocytes by fourcolor flow cytometry. Photochem Photobiol (1998) 67:565-572.
30. Obochi MOK, Canaan AJ, Jain AK, Richter AM, Levy JG: Targeting activated lymphocytes with photodynamic therapy: susceptibility of mitogen-stimulated splenic lymphocytes to benzoporphyrin derivative (BPD) photosensitization. Photochem Photobiol (1995) 62:169-175.
31. Canti G, Marelli O, Ricci L, Nicolin A: Haematoporphyrin-treated murine lymphocytes: In vitro inhibition of DNA synthesis and light-mediated inactivation of cells responsible for GVHR. Photochem Photobiol (1981) 34:589-594.
32. Hunt DWC, Jiang H, Granville DJ, Chan AH, Leong S, Levy JG: Consequences of the photodynamic treatment of resting and activated peripheral T lymphocytes. Immunopharacology. In press.
33. Granville DJ, Jiang H, An MT, Levy JG, McManus BM, Hunt DWC: Overexpression of Bel-XL prevents caspase-3mediated activation of DNA fragmentation factor (OFF) produced by treatment with the photochemotherapeutic agent BPD-MA. FEBS Letters (1998) 422:151-154.
34. Verma A, Facchina SL, Hirsch DJ, Song S-Y. Dillahey LF, Williams JR, Snyder SH: Photodynamic tumor therapy: mitochondrial benzodiazepine receptors as a therapeutic target Mol Med (1998) 4:40-45.
35. Verma A, Nye JS, Snyder SH: Porphyrins are endogenous ligands for the mitochondrial (peripheral-type) benzodiazepine receptor. Proc Natt Acad Sei USA (1987) 84:2256-2260.
36. Carayon P, Portier M, Dussossoy D, Bord A, Petitpretre G, Canal X, Le Fur G, Casellas P: Involvement of peripheral benzodiazepine receptors in the protection of hematopoietic cells against oxygen radical damage. Blood (1996) 87:3170-3178.
37. Grüner S, Volk H. Noack F, Meffert H, Von Baehr R: Inhibition of HLA-DR antigen expression and of the mixed leukocyte reaction by photochemical treatment Tissue Antigens (1986) 27:147-154.
38. Krutman J, Athar M, Mendel DB, Khan IU. Guyre PM, Mukhtar H, Elmets CA: Inhibition of the high affinity Fc receptor (FcRI) on human monocytes by porphyrin photosensrtization Is highly specific and mediated by the generation of Superoxide radicals. JBiol Chem (1989) 264:11407-11413.
39. Steinman RM: The dendritic cell system and its role in immunogenicity. Ann Rev Immunol(1991) 9:271-296.
40. Grüner S, Meffert H, Volk D, Grunow R, Jahn S: The influence of haematoporphyrin derivative and visible light on murine skin graft survival, epidermal Langerhans cells and stimulation of the allogeneic mixed leukocyte reaction. Scand J Immunol (1985)21:267-273.
41. Obochi MOK, Ratkay LG, Levy JG: Prolonged skin allograft survival after photodynamic therapy (PDT) associated with modification of donor skin antigenicity. Transplantation (1997) 63:810-817.
42. King DE, Jiang H, Simkin GO, Obochi MOK, Levy JG, Hunt DWC: Photodynamic alteration of the surface receptor expression pattern of murine splenic dendritic cells. Scand J Immunol In press. t
43. Elmets CA, Bowen KD: Immunological suppression in mice treated with hematoporphyrin derivative photoradiation. Cancer Res (1986) 46:1608-1611.
44. Lynch DH, Haddad S, King VJ, Ott MJ, Straight RC, Jolies CJ: Systemic immunosuppression induced by photodynamic therapy (PDT) is adoptively transferred by macrophages. Photochem Photobiol (1989) 49:453-458.
45. Qin B, Selman SH, Payne KM, Keck RW, Metzger DW: Enhanced skin allograft survival after photodynamic therapy. Association with lymphocyte inactivation and macrophage stimulation. Transplantation (1993) 56:1481-1486.
46. Richter AM, Jain AK, Obochi M, Meadows H, Canaan AJ, Levy JG: Activation of benzoporphyrin derivative in the circulation of mice without skin photosensitivity. Photochem Photobiol (1994)59:350-355.
47. Leong S, Chan AH, Levy JG, Hunt DWG: Transcutaneous photodynamic therapy alters the development of an adoptively transferred form of murtne experimental autoimmune encephalomyelitis. Photochem Photobiol (1996) 64:751-757.
48. Chowdhary RK, Ratkay LG, Neyndorff HC, Richter A, Obochi M, Waterfield DJ, Levy JG: The use of transcutaneous photodynamic therapy in the prevention of adjuvant enhanced arthritis in MRL/lpr mice. Clin Immunol /mmuT7Cpafto/(1994) 72:255-263.
49. Ratkay. LG, Chowdhary RK, Neyndorff HC, Tonzetich J, Waterfield JD, Levy JG: Photodynamic therapy: a comparison with other immunomodulatory treatments of adjuvantenhanced arthritis in MRL/lpr mice. Clin Exp Immunol (1994) 95:373-377.
50. Simkin GO, King DE, Chan AH, Hunt DWC: Inhibition of contact hypersensitivity with different analogs of benzoporphyrin derivative. Immunopharmacology (1997) 37:221-230.
51. D'Andréa A, Aste-Amezaga M, Valiante NM, Ma X, Kubin M. Trinchieri: Interleukin 10 (IL-10) inhibits human lymphocyte Interferon -y-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Wed (1993) 178:1041-1048.
52. Enk AH, Angeloni VL, Udey MC. Katz SI: Inhibition of Langerhans cell antigen-presenting function by IL-10. A role for IL-10 in induction of tolerance. J Immunol (1993) 151:2390-2398.
53. Gottlieb SL, Gilleaudeau P, Johnson R, Estes L, Woodworth TG, Gottlieb AB, Krueger JG: Response of psoriasis to a lymphocyte-selective toxin (DAB.JL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nature Med (1995) 1:442-447.
54. Calzavara-Pinton PG, Szeimies R-M, Ortel B, Zane C: Photodynamic therapy with systemic administration of photosensitizers in dermatology. J Photochem Photobiol B:Biology (1996) 35:225-231.
55. Berg H, Bauer E, Gollnick FA, Diezel W, Bohm F, Meffert H, Sonnichsen N: Photodynamic therapy of psoriasis. In: Photodynamic Therapy of Tumors and Other Diseases. G Jori and C Perria (Eds), Progetto Editore, Padova (1985) pp 337343.
56. Bissonnette R, McLean Dl, Reid G, Kelsall J. Lui H: Photodynamic therapy of psoriasis and psoriatic arthritis with BPO verteporfin. Seventh Biennial Congress of the International Photodynamic Association. Nantes France, July 7-9, 1998. Abstract RC87.
57. Thomas R, Davis LS, LJpsky PE: Rheumatoid synovium Is enriched in mature antigen-presenting dendritic cells. J Immunol (1994) 152:2613-2623.